Detection of Tumor DNA in the Blood of Patients Receiving Standard Therapy for Hormone Receptor-positive (HR+) Non-HER2 Expressing (HER2-) Metastatic Breast Cancer as a Tool to Select Those Who May Benefit From the Next Course of Fulvestrant in Combination With Alpelisib or Ribociclib
Status: RECRUITING
Study type: INTERVENTIONAL
Conditions: Breast Cancer Stage IV
Interventions: DRUG: Alpelisib|DRUG: Ribociclib
Sponsor: UNICANCER
Collaborators: Novartis|Breast Cancer Research Foundation